NUTX Stock Analysis: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$196.53
5.82 (3.05%)
▲
5d:
+31.81%
30d:
+57.19%
90d:
+99.64%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
25d
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NUTX is 19.8% above its trading range ($164.11). Market expects 6.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NUTX is 19.8% above its trading range ($164.11). Market expects 6.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$210.64
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$130.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $196.53, which is considered extended relative to its 30-day fair value range of $126.62 to $164.11. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.5) compared to its historical average (7.0). At these levels, the market is pricing in 6.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $201.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: NUTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $246.40 (+25.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $201.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: NUTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $246.40 (+25.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$126.62 -
$164.11
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BEARISH: Price significantly overextended (+19.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 25.4% below Wall St target ($246.40)
- NEUTRAL: Trading at premium valuation - market expects 6.9% growth which is achievable
- WARNING: Recommendation downgraded due to 19.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$126.62 -
$164.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$142.92
Resistance Level
$201.49
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.53
Wall Street Target
$246.40
(+25.4%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
95.9%
Profit Margin
10.9%
Valuation Premium vs History
+6.9% premium
PE vs Historical
8.5 vs 7.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.9%
(market-implied from PE analysis)
1-Year Target
$210.09
(+7%)
2-Year Target
$224.59
(+14%)
3-Year Target
$240.08
(+22%)
3-Yr Target (if PE normalizes)
(PE: 9→7)
PE COMPRESSION
$196.94
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.0%)
$614.76
(+213%)
Base:
(SPY PE: 8.5, Growth: 7.0%)
$240.87
(+23%)
Bear:
(PE: 7.0, Growth: 7.0%)
$197.58
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 14.02 | Current EPS (TTM): $13.67
Bull Case
$355.12
(+81%)
Analyst growth 68.5%, PE expands to 15.4
Base Case
$322.84
(+64%)
Market implied 68.5%, PE stable at 14.0
Bear Case
$130.31
(-34%)
Severe decline -20.0%, PE contracts to 11.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 8:23 AM ET
Data refreshes hourly during market hours. Next update: 9:23 AM
Data refreshes hourly during market hours. Next update: 9:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Frank E Jaumot
BUY
150 shares
2026-03-20
Warren Hosseinion
BUY
252 shares
2026-03-19
Kelvin Spears
BUY
10 shares
2026-03-17
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$243 | 57 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$500 | 66 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 58 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 53 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 60 BUY |
